Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of Crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Blackhall, Fiona H Kim, D Besse, B Nokihara, H Han, J Wilner, K Reisman, A Iyer, S Hirsh, V Shaw, A
Blackhall, Fiona H
Kim, D
Besse, B
Nokihara, H
Han, J
Wilner, K
Reisman, A
Iyer, S
Hirsh, V
Shaw, A
Citations
Altmetric:
Abstract
The main objective of the current post hoc analysis was to compare patient-reported outcomes between crizotinib (N = 172) and chemotherapy subgroups (pemetrexed [N = 99] and docetaxel [N = 72]) in previously treated patients with advanced ALK-positive non-small-cell lung cancer, in PROFILE 1007 study (Pfizer; NCT0093283).
Description
Date
2014-11
Publisher
Collections
Keywords
Type
Article
Citation
Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of Crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. 2014, 9 (11):1625-33 J Thorac Oncol